JPH0558000B2 - - Google Patents

Info

Publication number
JPH0558000B2
JPH0558000B2 JP59086972A JP8697284A JPH0558000B2 JP H0558000 B2 JPH0558000 B2 JP H0558000B2 JP 59086972 A JP59086972 A JP 59086972A JP 8697284 A JP8697284 A JP 8697284A JP H0558000 B2 JPH0558000 B2 JP H0558000B2
Authority
JP
Japan
Prior art keywords
interferon
solution
amino acids
ifn
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP59086972A
Other languages
English (en)
Japanese (ja)
Other versions
JPS60243028A (ja
Inventor
Yasuki Kato
Eiji Hayakawa
Kunitoshi Furuya
Akira Kondo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Priority to JP59086972A priority Critical patent/JPS60243028A/ja
Priority to EP85104849A priority patent/EP0163111B1/en
Priority to DE8585104849T priority patent/DE3579942D1/de
Priority to CA000479841A priority patent/CA1264665A/en
Priority to US06/726,971 priority patent/US4675183A/en
Publication of JPS60243028A publication Critical patent/JPS60243028A/ja
Publication of JPH0558000B2 publication Critical patent/JPH0558000B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP59086972A 1984-04-28 1984-04-28 インタ−フエロンの可溶化方法 Granted JPS60243028A (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP59086972A JPS60243028A (ja) 1984-04-28 1984-04-28 インタ−フエロンの可溶化方法
EP85104849A EP0163111B1 (en) 1984-04-28 1985-04-22 Method for solubilization of interferon
DE8585104849T DE3579942D1 (de) 1984-04-28 1985-04-22 Verfahren zum loesbarmachen von interferon.
CA000479841A CA1264665A (en) 1984-04-28 1985-04-23 Method for solubilization of interferon
US06/726,971 US4675183A (en) 1984-04-28 1985-04-25 Method for solubilization of interferon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59086972A JPS60243028A (ja) 1984-04-28 1984-04-28 インタ−フエロンの可溶化方法

Publications (2)

Publication Number Publication Date
JPS60243028A JPS60243028A (ja) 1985-12-03
JPH0558000B2 true JPH0558000B2 (en, 2012) 1993-08-25

Family

ID=13901785

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59086972A Granted JPS60243028A (ja) 1984-04-28 1984-04-28 インタ−フエロンの可溶化方法

Country Status (5)

Country Link
US (1) US4675183A (en, 2012)
EP (1) EP0163111B1 (en, 2012)
JP (1) JPS60243028A (en, 2012)
CA (1) CA1264665A (en, 2012)
DE (1) DE3579942D1 (en, 2012)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0168008A3 (en) * 1984-07-10 1986-12-30 Takeda Chemical Industries, Ltd. Stable composition of gamma-interferon
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
DE3744542B4 (de) * 1987-12-30 2004-06-03 Hoerrmann, Wilhelm, Dr. Pharmazeutische Verwendung von L-δ-Hydroxylysin
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
WO1990006764A1 (en) * 1988-12-15 1990-06-28 Invitron Corporation Use of basic amino acids to solubilize immunoglobulins
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US6270757B1 (en) * 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6399296B1 (en) * 1994-07-20 2002-06-04 The General Hospital Corporation Interaction trap systems for detecting protein interactions
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
WO1996024369A1 (en) * 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
US6126933A (en) * 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US6540993B1 (en) * 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
PT948358E (pt) * 1996-12-24 2004-10-29 Biogen Idec Inc Formulacoes de interferao liquidas e estaveis
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
UY27373A1 (es) * 2001-07-09 2003-02-28 Schering Ag Formulaciones de interferón beta-humano
NZ534378A (en) * 2002-02-22 2006-10-27 Schering Corp Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
EP1938798A1 (en) * 2002-02-22 2008-07-02 Schering Corporation Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
AR042453A1 (es) * 2002-12-13 2005-06-22 Otsuka Pharma Co Ltd Una composicion de interferon-gamma liofilizada para administracion transpulmonar y un sistema para su inhalacion
US20070071840A1 (en) * 2005-09-27 2007-03-29 Sridevi Dhanaraj Method for treatment of cartilage disorders with centella extract
CA2686848A1 (en) * 2007-05-08 2008-11-20 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5821691A (ja) * 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd α−及びβ−インタ−フェロンの精製方法
ZA828580B (en) * 1981-12-23 1983-10-26 Schering Corp Interferon formulations
DE3262575D1 (en) * 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
US4432895A (en) * 1982-11-24 1984-02-21 Hoffmann-La Roche Inc. Monomeric interferons
JPS59181223A (ja) * 1983-03-29 1984-10-15 Sumitomo Chem Co Ltd インタ−フエロンの安定化法
JPS59181224A (ja) * 1983-03-29 1984-10-15 Sumitomo Chem Co Ltd 安定なインタ−フエロン製剤の製法
EP0168008A3 (en) * 1984-07-10 1986-12-30 Takeda Chemical Industries, Ltd. Stable composition of gamma-interferon

Also Published As

Publication number Publication date
JPS60243028A (ja) 1985-12-03
EP0163111B1 (en) 1990-10-03
EP0163111A3 (en) 1987-09-30
EP0163111A2 (en) 1985-12-04
DE3579942D1 (de) 1990-11-08
CA1264665A (en) 1990-01-23
US4675183A (en) 1987-06-23

Similar Documents

Publication Publication Date Title
JPH0558000B2 (en, 2012)
CA1329542C (en) Plasma and recombinant protein formulations in low ionic strength media
JP2544968B2 (ja) 高イオン性濃度媒体中の血漿及び組換え蛋白処方物
JP2966592B2 (ja) 安定化されたヒトモノクローナル抗体製剤
JPS60258125A (ja) 蛋白性生理活性物質を含有する水溶性乾燥物
JP2004196824A (ja) エリスロポエチン溶液製剤
JPH0770195A (ja) 糖修飾インターフェロン
TWI285112B (en) Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer
Lee et al. Outer membrane proteins of Eschrichia coli: Biosynthesis and assembly
EP0364491A1 (en) Stabilized formulations of gamma interferons
JPS59181224A (ja) 安定なインタ−フエロン製剤の製法
SU1012786A3 (ru) Способ получени протеинового комплекса,стимулирующего секрецию инсулина
JP3544180B2 (ja) 安定化した顆粒球コロニー刺激因子
JP4332694B2 (ja) 水溶性乾燥組成物
KR930008908B1 (ko) 조직형 플라스미노겐 활성화제 또는 그의 유도체를 함유하는 혈전용해 조성물
JP2708749B2 (ja) 修飾型ｔＰＡ含有注射用組成物
US6387695B1 (en) DNA pharmaceutical formulations comprising citrate or triethanolamine and combinations thereof
JPH03130232A (ja) 安定化白血球インタフェロン
FI98891C (fi) Menetelmä vesiliuoksen proteiinipitoisuuden lisäämiseksi
JPS6059000A (ja) インタ−フェロンの安定化方法
JPS62153224A (ja) プラスミノゲン製剤
RU2809360C1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДА pET32a-IFG144, ОБЕСПЕЧИВАЮЩАЯ СИНТЕЗ ИНТЕРФЕРОНА ГАММА, ШТАММ БАКТЕРИЙ ESCHERICHIA COLI JM109/pET32a-IFG144 - ПРОДУЦЕНТ БЕЛКА ИНТЕРФЕРОН ГАММА, СПОСОБ ПОЛУЧЕНИЯ ИНТЕРФЕРОНА ГАММА И ЛЕКАРСТВЕННОЕ СРЕДСТВО
JPH0597703A (ja) 改変型組織プラスミノーゲン活性化因子含有組成物
RU2294372C1 (ru) СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА АЛЬФА-2b И ИНТЕРФЕРОНСОДЕРЖАЩИЙ ПРЕПАРАТ (ВАРИАНТЫ)
JPS60155136A (ja) γ型インタ−フエロン組成物